NetworkNewsBreaks – Regentis Biomaterials Ltd. (NYSE American: RGNT) Appoints Dr. Galit Reske as Chief Medical Officer
Regentis Biomaterials (NYSE American: RGNT), a regenerative medicine company focused on tissue repair solutions, today announced the appointment of Dr. Galit Reske, PhD, as chief medical officer. Dr. Reske brings extensive experience in clinical development, regulatory strategy and global clinical operations, including leadership of CartiHeal’s IDE pivotal study for the Agili-C(TM) cartilage repair implant and support of the product’s U.S. FDA approval in 2022 prior to CartiHeal’s acquisition by Smith+Nephew in 2023. To view the full press release, visit https://ibn.fm/6kjsX About Regentis Biomaterials Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore…







